Literature DB >> 33922803

Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades.

Michele Simbolo1,2, Mirna Bilotta3,4,5, Andrea Mafficini1,2,6, Claudio Luchini1,2, Daniela Furlan7, Frediano Inzani4,5, Gianluigi Petrone4,5, Davide Bonvissuto8, Stefano La Rosa7,9, Giovanni Schinzari5,10, Antonio Bianchi4,11, Ernesto Rossi10, Roberta Menghi4,12, Felice Giuliante4,13, Stefania Boccia14, Aldo Scarpa1,2,6, Guido Rindi3,4,5.   

Abstract

Pancreatic neuroendocrine tumors (PanNETs) display variable aggressive behavior. A major predictor of survival is tumor grade based on the Ki67 proliferation index. As information on transcriptomic profiles of PanNETs with different tumor grades is limited, we investigated 29 PanNETs (17 G1, 7 G2, 5 G3) for their expression profiles, mutations in 16 PanNET relevant genes and LINE-1 DNA methylation profiles. A total of 3050 genes were differentially expressed between tumors with different grades (p < 0.05): 1279 in G3 vs. G2; 2757 in G3 vs. G1; and 203 in G2 vs. G1. Mutational analysis showed 57 alterations in 11 genes, the most frequent being MEN1 (18/29), DAXX (7/29), ATRX (6/29) and MUTYH (5/29). The presence and type of mutations did not correlate with the specific expression profiles associated with different grades. LINE-1 showed significantly lower methylation in G2/G3 versus G1 tumors (p = 0.007). The expression profiles of matched primaries and metastasis (nodal, hepatic and colorectal wall) of three cases confirmed the role of Ki67 in defining specific expression profiles, which clustered according to tumor grades, independently from anatomic location or patient of origin. Such data call for future exploration of the role of Ki67 in tumor progression, given its involvement in chromosomal stability.

Entities:  

Keywords:  Ki67; LINE-1; NET; gene expression profiling; grade; neuroendocrine tumor; pancreas

Year:  2021        PMID: 33922803     DOI: 10.3390/cancers13092054

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  33 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

3.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data.

Authors:  Zuguang Gu; Roland Eils; Matthias Schlesner
Journal:  Bioinformatics       Date:  2016-05-20       Impact factor: 6.937

4.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

5.  Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.

Authors:  Michele Stefanoli; Stefano La Rosa; Nora Sahnane; Chiara Romualdi; Roberta Pastorino; Alessandro Marando; Carlo Capella; Fausto Sessa; Daniela Furlan
Journal:  Neuroendocrinology       Date:  2014-07-05       Impact factor: 4.914

6.  Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Authors:  Ilaria Marinoni; Anja Schmitt Kurrer; Erik Vassella; Matthias Dettmer; Thomas Rudolph; Vanessa Banz; Fabio Hunger; Silvan Pasquinelli; Ernst-Jan Speel; Aurel Perren
Journal:  Gastroenterology       Date:  2013-10-19       Impact factor: 22.682

7.  Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor.

Authors:  William McLaren; Bethan Pritchard; Daniel Rios; Yuan Chen; Paul Flicek; Fiona Cunningham
Journal:  Bioinformatics       Date:  2010-06-18       Impact factor: 6.937

8.  The prognostic value of global DNA hypomethylation in cancer: a meta-analysis.

Authors:  Jinhui Li; Qingyuan Huang; Fangfang Zeng; Wenxue Li; Zhini He; Wen Chen; Wei Zhu; Bo Zhang
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

9.  ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.

Authors:  Chang S Chan; Saurabh V Laddha; Peter W Lewis; Matthew S Koletsky; Kenneth Robzyk; Edaise Da Silva; Paula J Torres; Brian R Untch; Janet Li; Promita Bose; Timothy A Chan; David S Klimstra; C David Allis; Laura H Tang
Journal:  Nat Commun       Date:  2018-10-12       Impact factor: 14.919

Review 10.  Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Andrea Mafficini; Aldo Scarpa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

View more
  1 in total

Review 1.  The Utility of Endoscopic-Ultrasonography-Guided Tissue Acquisition for Solid Pancreatic Lesions.

Authors:  Hiroki Tanaka; Shimpei Matsusaki
Journal:  Diagnostics (Basel)       Date:  2022-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.